Effect of HIV on women

AIDS Reader

Volumn 16, Issue 7, 2006, Pages

  Gray, Glenda E ^a   McIntyre, James A ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Antiretroviral treatment; HIV AIDS; Mother to child transmission; Women

Indexed keywords

ANTIRETROVIRUS AGENT; CLOTRIMAZOLE; CONTRACEPTIVE AGENT; CYTOCHROME P450; DIDANOSINE; EFAVIRENZ; ETHINYLESTRADIOL; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MICONAZOLE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE;

CANDIDA; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG USE; FEMALE; FEMALE FERTILITY; GENDER; HETEROSEXUALITY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; LACTIC ACIDOSIS; NEURAL TUBE DEFECT; PELVIC INFLAMMATORY DISEASE; PREGNANCY OUTCOME; PRIMARY PREVENTION; REVIEW; RISK FACTOR; SAFE SEX; TERATOGENICITY; UNSAFE SEX; UTERINE CERVICITIS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VAGINA CANDIDIASIS; VIRUS INFECTION; VIRUS TRANSMISSION; WART VIRUS;

EID: 33750445936     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Joint United Nations Program on HIV/AIDS (UNAIDS). 2006 Report on the global AIDS epidemic. Available at: http://www.unaids.org/en/HIV-data/ 2006GlobalReport.
2. Centers for Disease Control and Prevention. HIV transmission among black women-North Carolina, 2004. MMWR. 2005;54:89-94.
3. Centers for Disease Control and Prevention. Diagnoses of HIV/AIDS-32 states, 2000-2003. MMWR. 2004;53:1106-1110.
4. Ramjee C, Williams B, Gouws E, et al. The impact of incident and prevalent herpes simplex virus-2 infection on the incidence of HIV-1 infection among commercial sex workers in South Africa. J Acquir Immune Defic Syndr. 2005;39:333-339.
5. Auvert B, Ballard R, Campbell C, et al. HIV infection among youth in a South African mining town is associated with herpes simplex virus-2 seropositivity and sexual behaviour. AIDS. 2001;15:885-898.
6. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis. 2002;185:45-52.
7. Serwadda D, Gray RH, Sewankambo NK, et al. Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. J Infect Dis. 2003;188:1492-1497.
8. Lazzarin A, Saracco A, Musicco M, Nicolosi A. Man-to-woman sexual transmission of the human immunodeficiency virus. Risk factors related to sexual behavior, man's infectiousness, and woman's susceptibility. Italian Study Group on HIV Heterosexual Transmission [published correction appears in Arch Intern Med. 1992;152:876]. Arch Intern Med. 1991;151:2411-2416.
9. Myer L, Denny L, Telerant R, et al. Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study. J Infect Dis. 2005;192:1372-1380.
10. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2:e298.
11. Gray RH, Li X, Kigozi G, et al. Increased risk of incident HIV during pregnancy in Rakai, Uganda: a, prospective study. Lancet. 2005;366:1182-1188.
12. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921-929.
13. Willerford DM, Bwayo JJ, Hensel M, et al. Human immunodeficiency virus infection among high-risk seronegative prostitutes in Nairobi. J Infect Dis. 1993; 167:1414-1417.
14. Padian NS, Shiboski SC, Glass OS, Vittinghoff E. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results of a ten-year study. Am J Epidemiol. 1997;146:350-357.
15. Dunkle KL, Jewkes RK, Brown HC, et al. Gender-based violence, relationship power, and risk of HIV infection among women attending antenatal clinics in South Africa. Lancet. 2004;363:1415-1421.
16. Dean HD, Lee LM, Thompson M, Dannemiller T. Impact of HIV on women in the United States [conference summary]. Emerg Infect Dis [serial on the Internet]. 2004. Available at: http://www.cdc.gov/ncidod/EID/vol10no11/04-0623_08.htm. Accessed May 2, 2006.
17. Clemetson DB, Moss GB, Willerford DM, et al. Detection of HIV DNA in cervical and vaginal secretions. Prevalence and correlates among women in Nairobi, Kenya. JAMA. 1993;269:2860-2864.
18. Pettifor AE, Rees HV, Kleinschmidt I, et al. Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. AIDS. 2005;19:1525-1534.
19. United Nations, Department of Economic and Social Affairs, Population Division. World Contraceptive Use 2003. New York: United Nations; 2004. Available at: http://www.un.org/esa/population/publications/contraceptive2003/ wcu2003.htm. Accessed May 5, 2006.
20. Morrison CS, Richardson BA, Celentano DD, et al. Prospective clinical trials designed to assess the use of hormonal contraceptives and risk of HIV acquisition. J Acquir Immune Defic Syndr. 2005;38(suppl 1):S17-S18.
21. Shah I. Contraceptive use patterns in countries with different levels of HIV epidemic. J Acquir Immune Defic Syndr. 2005;38(suppl 1):S5-S6.
22. Wang CC, Reilly M, Kreiss JK. Risk of HIV infection in oral contraceptive pill users: a meta-analysis [published correction appears in J Acquir Immune Defic Syndr. 1999;21:428]. J Acquir Immune Defic Syndr. 1999;21:51-58.
23. Martin HL Jr, Richardson BA, Mandaliya K, et al. The early work on hormonal contraceptive use and HIV acquisition. J Acquir Immune Defic Syndr. 2005; 38(suppl 1):S12-S14.
24. Plourde PJ, Pepin J, Agoki E, et al. Human immunodeficiency virus type 1 seroconversion in women with genital ulcers. J Infect Dis. 1994;170:313-317.
25. Kilmarx FH, Mock PA, Levine WC. Effect of Chlamydia trachomatis coinfection on HIV shedding in genital tract secretions. Sex Transm Dis. 2001;28: 347-348.
26. Lavreys L, Baeten JM, Martin HL Jr, et al. Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study. AIDS. 2004; 18:695-697.
27. Coombs RW, Reichelderfer PS, Landay AL. Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS. 2003;17:455-480.
28. Daly CC, Helling-Giese GE, Mati JK, Hunter DJ. Contraceptive methods and the transmission of HIV: implications for family planning. Genitourin Med. 1994;70:110-117.
29. Kiddugavu M, Makumbi F, Wawer MJ, et al; Rakai Project Study Group. Hormonal contraceptive use and HIV-1 infection in a population-based cohort in Rakai, Uganda. AIDS. 2003;17:233-240.
30. World Health Organization. Hormonal contraception and HIV. Presented at the Science and Policy Africa Regional Meeting; September 19-21, 2005; Nairobi, Kenya.
31. Schuman P, Ohmit SE, Klein RS, et al; HIV Epidemiology Study (HERS) Group. Longitudinal study of cervical squamous intraepithelial lesions in human immundeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis. 2003;188:128-136.
32. Maiman M, Fruchter RG, Sedlis A, et al. Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with human immunodeficiency virus. Gynecol Oncol. 1998;68:233-239.
33. Wright TC Jr, Ellerbrock TV, Chiasson MA, et al. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. Obstet Gynecol. 1994;84:591-597.
34. Schuman P, Sobel JD, Ohmit SE, et al. Mucosal candidal colonization and candidiasis in women with or at risk for human immunodeficiency virus infection. HIV Epidemiology Research Study (HERS) Group. Clin Infect Dis. 1998;27:1161-1167.
35. Duerr A, Sierra MF, Feldman J, et al. Immune compromise and prevalence of Candida vulvovaginitis in human immunodeficiency virus-infected women. Obstet Gynecol 1997;90:252-256.
36. Sobel JD. Vulvovaginal candidiasis: a comparison of HIV-positive and -negative women. Int J STD AIDS. 2002;13:358-362.
37. Irwin KL, Moorman AC, O'Sullivan MJ, et al. Influence of human immunodeficiency virus infection on pelvic inflammatory disease. Obstet Gynecol. 2000; 95:525-534.
38. Sebitloane MH. HIV and gynaecological infections. Best Pract Res Clin Obstet Gynaecol. 2005;19: 231-241.
39. Korn AP. Pelvic inflammatory disease in women infected with MV. AIDS Patient Care STDS. 1998;12: 431-434.
40. Glynn JR, Buve A, Carael M, et al. Decreased fertility among HIV-1-infected women attending antenatal clinics in three African cities. J Acquir Immune Defic Syndr. 2000;25:345-352.
41. Loko MA, Toure S, Dakoury-Dogbo N, et al. Decreasing incidence of pregnancy by decreasing CD4 cell count in HIV-infected women in Cote d'Ivoire: a 7-year cohort study. AiDS. 2005;19:443-445.
42. Gray RH, Wawer MJ, Serwadda D, et al. Population-based study of fertility in women with HIV-1 infection in Uganda. Lancet. 1998;351:98-103.
43. Lee LM, Wortley PM, Fleming PL, et al. Duration of human immunodeficiency virus infection and likelihood of giving birth in a Medicaid population in Maryland. Am J Epidemiol. 2000;151:1020-1028.
44. Nguyen RH, Gray RH, Anderson JR, et al. Delayed conception among HIV-positive women in the Women's Interagency HIV Study (WIHS). Presented at the 36th Annual Meeting of the Society for Epidemiological Research (SER); June 11-14, 2003; Atlanta. Poster 193-S.
45. French R, Brocklehurst P. The effect of pregnancy on survival in women infected with HIV: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol. 1998;105:827-835.
46. Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol. 1998;105:836-848.
47. Castetbon K, Ladner J, Leroy V, et al. Low birth-weight in infants born to African HIV-infected women: relationship with maternal body weight during pregnancy: Pregnancy and HIV Study Group (EGE). J Trop Pediatr. 1999;45(3):152-157.
48. Coley JL, Msamanga GI, Fawzi MC, et al. The association between maternal HIV-1 infection and pregnancy outcomes in Dar es Salaam, Tanzania. BJOG. 2001;108:1125-1133.
49. Ladner J, Leroy V, Hoffman P, et al. Chorioamnionitis and pregnancy outcome in HIV-infected African women. Pregnancy and HIV Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18: 293-298.
50. Ticconi C, Mapfumo M, Dorrucci M, et al. Effect of maternal HIV and malaria infection on pregnancy and perinatal outcome in Zimbabwe. J Acquir Immune Defic Syndr. 2003;34:289-294.
51. Mofenson LM. Mother-child HIV-1 transmission: timing and determinants. Obstet Gynecol Clin North Am. 1997;24:759-784.
52. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40: 458-465.
53. Mofenson LM. Successes and challenges in the perinatal HIV-1 epidemic in the United States as illustrated by the HIV-1 serosurvey of childbearing women. Arch Pediatr Adolesc Med. 2004;158:422-425.
54. Lallemant M, Jourdain G, Le Coeur S, et al; Perinatal HIV Prevention Trial (Thailand) Investigators. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004;351:217-228.
55. Dabis F, Bequet L, Ekouevi DK, et al; ANRS 1201/1202 DITRAME PLUS Study Group. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS. 2005;19:309-318.
56. Cooper ER, Charurat M, Mofenson L, et al; Women and Infants' Transmission Study Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-494.
57. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS. 2004;18:2337-2339.
58. European Collaborative Study; Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS. 2000;14: 2913-2920.
59. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;346: 1863-1870.
60. Tuomala RE, Watts DH, Li D, et al; Women and Infants Transmission Study. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. 2005;38:449-473.
61. Leith J, Piliero P, Storfer S, et al. Appropriate use of nevirapine for long-term therapy. J Infect Dis. 2005; 192:545-546.
62. Hitti J, Frenkel LM, Stek AM, et al; PACTG 1022 Study Team. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr. 2004;36:772-776.
63. Timmermans S, Tempelman C, Godfried MH, et al; Dutch HMF Study Group. Nelfinavir and nevirapine side effects during pregnancy. AIDS. 2005;19: 795-799.
64. Chersich MF, Gray GE. Progress and emerging challenges in preventing mother-to-child transmission. Curr Infect Dis Rep. 2005;7:393-400.
65. Leroy V, Sakarovitch C, Cortina-Borja M, et al; Ghent Group on HIV in Women and Children. Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa? AIDS. 2005;19:1865-1875.
66. Chaix ML, Dabis F, Ekouevi D, et al. Addition of 3 days of ZDV+3TC postpartum to a short course of ZDV+3TC and single-dose NVP provides low rate of NVP resistance mutations and high efficacy in preventing peri-partum HIV-1 transmission: ANRS DITRAME Plus, Abidjan, Côte d'Ivoire. Presented at the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25,2005; Boston. Abstract 72LB.
67. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis. 2005; 192:30-36.
68. Martinson N, Morris L, Gray G, et al. HIV resistance and transmission following single-dose nevirapine in a PMTCT cohort. Presented at the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco. Abstract 38.
69. Johnson JA, Li JF, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis. 2005;192:16-23.
70. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al; Perinatal HIV Prevention Trial Group. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004;351:229-240.
71. McIntyre JA, Martinson N, Gray GE, et al. Addition of short course Combivir to single dose Viramune for the prevention of mother to child transmission of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI-resistant virus. Presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 24-27, 2005; Rio de Janeiro. Abstract TuFo0204.
72. World Health Organization. Antiretroviral drugs and the prevention of mother-to-child transmission of HIV infection in resource-limited settings. Report of a Technical Consultation; February 5-6, 2004; Geneva. Available at: http://www.who.int/reproductive-health/stis/docs/arvddrugsmeetingreport.pdf. Accessed May 3, 2006.
73. Thorne C, Newell ML. Prevention of mother-to-child transmission of HIV infection. Curr Opin Infect Dis. 2004;17:247-252.
74. McIntyre J. Preventing mother-to-child transmission of HIV: successes and challenges. BJOG. 2005; 112:1196-1203.
75. Rollins N, Meda N, Becquet R, et al; Ghent IAS Working Group on HIV in Women and Children. Preventing postnatal transmission of HIV-1 through breast-feeding: modifying infant feeding practices. J Acquir Immune Defic Syndr. 2004;35:188-195.
76. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med. 1995;333:751-756.
77. Melnick SL, Sherer R, Louis TA, et al. Survival and disease progression according to gender of patients with HIV infection. The Terry Beirn Community Programs for Clinical Research on AIDS. JAMA. 1994;272:1915-1921.
78. Gandhi M, Bacchetti P, Miotti P, et al. Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis. 2002;35:313-322.
79. Sterling TR, Vlahov D, Astemborski J, et al. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med. 2001;344: 720-725.
80. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. November 10, 2003. Supplement: Considerations for antiretroviral therapy in women. Available at: http://www. aidsinfo.nih.gov/Guidelines/ArchivedGuidelines. aspx?MenuItem=Guidelines&Search=Off& GuidelineID=18&ClassID=6. Accessed May 9, 2006.
81. van Benthem BH, Vernazza P, Coutinho RA, Prins M; European Study on the Natural History of HIV Infection in Women and the Swiss HIV Cohort Study. The impact of pregnancy and menopause on CD4 lymphocyte counts in HIV-infected women. AIDS. 2002;16:919-924.
82. van Benthem BH, Vernazza P, Coutinho RA, Prins M. Impact of pregnancy and menopause on CD4 cell counts. J Acquir Immune Defic Syndr. 2005; 38(suppl 1):S22.
83. Arnsten JH, Freeman R, Howard AA, et al. HIV infection and bone mineral density in middle-aged women. Clin Infect Dis. 2006;42:1014-1020. Epub Feb 24, 2006.
84. Gifford AL, Cunningham WE, Heslin KC, et al; HIV Cost and Services Utilization Study Consortium. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med. 2002;346:1373-1382.
85. Hader SL, Smith DK, Moore JS, Holmberg SD. HIV infection in women in the United States: status at the millennium. JAMA. 2001;285:1186-1192.
86. Kuyper LM, Wood E, Montaner JS, et al. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-infected patients in a population-based cohort. J Acquir Immune. Defic Syndr. 2004;37:1470-1476.
87. O'Connell JM, Braitstein P, Hogg RS, et al. Age, adherence and injection drug use predict virological suppression among men arid women enrolled in a population-based antiretroviral drug treatment programme. Antivir Ther. 2003;8(6):569-576.
88. Arenas-Pinto A, Grant AD, Edwards S, Weller IV. Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Infect. 2003; 79:340-343.
89. Galli M, Ridolfo AL, Adomi F, et al. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy. Antivir Ther. 2003;8: 347-354.
90. Galli M, Veglia F, Angarano G, et al. Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr. 2003;34:58-61.
91. Chu JH, Gange SJ, Anastos K, et al. Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy. Am J Epidemiol. 2005;161: 881-890.
92. De Rossi A, Omette L, Masiero S, et al. Viral phenotype in mother-to-child HIV-1 transmission and disease progression of vertically acquired HIV-1 infection. Acta Paediatr Suppl. 1997;421:22-28.
93. Ometto L, Zanotto C, Maccabruni A, et al. Viral phenotype and host-cell susceptibility to HIV-1 infection as risk factors for mother-to-child HIV-1 transmission. AIDS. 1995;9:427-434.
94. Casper CH, Clevestig P, Carlenor E, et al. Link between the X4 phenotype in human immunodeficiency virus type 1-infected mothers and their children, despite the early presence of R5 in the child. J Infect Dis. 2002;186:914-921.
95. Blackard JT, Renjifo B, Fawzi W, et al. HIV-1 LTR subtype and perinatal transmission. Virology. 2001; 287:261-265.
96. Ometto L, Zanchetta M, Mainardi M, et al. Coreceptor usage of HIV-1 primary isolates, viral burden, and CCR5 genotype in mother-to-child HIV-1 transmission. AIDS. 2000;14:1721-1729.
97. Philpott S, Burger H, Charbonneau T, et al. CCR5 genotype and resistance to vertical transmission of HIV-1. J Acquir Immune Defic Syndr. 1999;21:189-193.
98. Fawzi W, Msamanga G, Renjifo B, et al. Predictors of intrauterine and intrapartum transmission of HIV-1 among Tanzanian women. AIDS. 2001;15: 1157-1165.
99. Mandelbrot L, Mayaux MJ, Bongain A, et al. Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. SEROGEST French Pediatric HIV Infection Study Group. Am J Obstet Gynecol. 1996; 175(3 pt 1):661-667.
100. Matheson PB, Thomas PA, Abrams EJ, et al. Heterosexual behavior during pregnancy and perinatal transmission of HIV-1. New York City Perinatal HIV Transmission Collaborative Study Group. AIDS. 1996;10:1249-1256.
101. Goldenberg RL, Vermund SH, Goepfert AR, Andrews WW. Choriodecidual inflammation: a potentially preventable cause of perinatal HIV-1 transmission? Lancet. 1998;352:1927-1930.
102. Mwanyumba F, Gaillard P, Inion I, et al. Placental inflammation and perinatal transmission of HIV-1. J Acquir Immune Defic Syndr. 2002;29:262-269.
103. Bhoopat L, Khunamornpong S, Sirivatanapa P, et al. Chorioamnionitis is associated with placental transmission of human immunodeficiency virus-1 subtype E in the early gestational period. Mod Pathol. 2005;18:1357-1364.
104. Evidence-Based Medicine Gray RH, Li X, Kigozi G, et al. Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet. 2005;366:1182-1188.
105. Hitti J, Frenkel LM, Stek AM, et al; PACTG 1022 Study Team. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr. 2004;36:772-776.
106. Loko MA, Toure S, Dakoury-Dogbo N, et al. Decreasing incidence of pregnancy by decreasing CD4 cell count in HIV-infected women in Cote d'Ivoire: a 7-year cohort study. AIDS. 2005;19:443-445.
107. Martin HL Jr, Richardson BA, Mandaliya K, et al. The early work on hormonal contraceptive use and HIV acquisition. J Acquir Immune Defic Syndr. 2005; 38(suppl 1):S12-S14.
108. Management Guidelines Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. November 10, 2003. Supplement: Considerations for antiretroviral therapy in women. Available at: http://www.aidsinfo. nih.gov/Guidelines/ArchivedGuidelines. aspx? MenuItem=Guidelines&Search=Off&GuidelineID= 18&ClassID=6. Accessed May 9, 2006.